What is EpicentRx?
Headquartered in La Jolla, California, EpicentRx operates at the intersection of advanced biotechnology and oncology. The company is dedicated to the research and development of novel therapeutic agents designed to address the inherent toxicity challenges often associated with traditional cancer treatments. By leveraging a sophisticated understanding of immune system modulation, EpicentRx aims to redefine the standard of care for patients battling complex tumor profiles. Their market position is defined by a commitment to precision medicine, ensuring that pharmaceutical efficacy is maximized while minimizing systemic patient harm. This focus on patient-centric drug design positions the firm as a critical innovator within the competitive immuno-oncology sector, where the demand for safer, more effective treatment modalities remains at an all-time high.
How much funding has EpicentRx raised?
EpicentRx has raised a total of $35M across 1 funding round:
Series D
$35M
Series D (2019): $35M with participation from Biotech Alliances International
Key Investors in EpicentRx
Biotech Alliances International
Biotech Alliances International is a Miami-based life science advisory firm that specializes in providing strategic insights and capital raising advisory services to biotechnology and pharmaceutical companies.
What's next for EpicentRx?
With the successful closure of this major enterprise-level funding round, EpicentRx is well-positioned to accelerate its clinical development pipeline and expand its research capabilities. The strategic deployment of this capital will likely focus on advancing lead candidates through rigorous regulatory milestones and scaling operational infrastructure to support long-term growth. As the company transitions into its next phase of development, the focus will remain on validating its proprietary platform and establishing key partnerships that can facilitate the commercialization of its therapeutic portfolio. Investors and industry observers will be closely monitoring the firm's progress as it seeks to translate its scientific breakthroughs into tangible clinical outcomes, potentially setting a new benchmark for safety and efficacy in the oncology market.
See full EpicentRx company page
